Details of the Drug Combinations

General Information of This Drug (ID: DMGM2Z6)

Drug Name

Lonafarnib DMGM2Z6

Synonyms

Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE

Indication

Disease Entry	ICD 11	Status	REF
Hutchinson-Gilford progeria syndrome	LD2B	Approved	[1]
Myelodysplastic syndrome	2A37	Phase 3	[2]
Hepatitis D virus infection	1E51.2	Phase 2	[3]
Non-small-cell lung cancer	2C25.Y	Discontinued in Phase 3	[4]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + Lonafarnib	DCL9287	Docetaxel	Lung Cancer	[5]
Lonafarnib + Anastrozole	DCVMQMU	Anastrozole	Breast Cancer	[6]
Lonafarnib + Fenretinide	DCZCUK5	Fenretinide	Head and Neck Cancer	[7]
Lonafarnib + Ritonavir	DCLZJ2K	Ritonavir	Hepatitis D	[8]
Lonafarnib + Ritonavir	DCYZ8TN	Ritonavir	Chronic Hepatitis D Infection	[9]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT00109538) Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8024).
5	ClinicalTrials.gov (NCT00288444) Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
6	ClinicalTrials.gov (NCT00081510) Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
7	ClinicalTrials.gov (NCT00102635) 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
8	ClinicalTrials.gov (NCT02511431) Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
9	ClinicalTrials.gov (NCT02430181) Lonafarnib With and Without Ritonavir in HDV (LOWR-1)